138 related articles for article (PubMed ID: 18663536)
21. Effects of imatinib on normal hematopoiesis and immune activation.
Appel S; Balabanov S; Brümmendorf TH; Brossart P
Stem Cells; 2005 Sep; 23(8):1082-8. PubMed ID: 16140870
[TBL] [Abstract][Full Text] [Related]
22. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
23. Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.
Paquin D; Kim PS; Lee PP; Levy D
Bull Math Biol; 2011 May; 73(5):1082-100. PubMed ID: 20532990
[TBL] [Abstract][Full Text] [Related]
24. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
25. An "age"-structured model of hematopoietic stem cell organization with application to chronic myeloid leukemia.
Roeder I; Herberg M; Horn M
Bull Math Biol; 2009 Apr; 71(3):602-26. PubMed ID: 19101772
[TBL] [Abstract][Full Text] [Related]
26. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
27. Targeted cancer treatment: resisting arrest.
Wodarz D
Nat Med; 2006 Oct; 12(10):1125-6. PubMed ID: 17024205
[No Abstract] [Full Text] [Related]
28. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
29. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
30. [Cancer initiation as mini-evolution].
Iwasa Y
Tanpakushitsu Kakusan Koso; 2005 Dec; 50(15):1962-9. PubMed ID: 16363646
[No Abstract] [Full Text] [Related]
31. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
32. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
33. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
34. Hypolipemiant besides antileukemic effect of imatinib mesylate.
Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
[TBL] [Abstract][Full Text] [Related]
35. Chronic myeloid leukemia stem cells.
Kavalerchik E; Goff D; Jamieson CH
J Clin Oncol; 2008 Jun; 26(17):2911-5. PubMed ID: 18539972
[TBL] [Abstract][Full Text] [Related]
36. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
Leuk Res; 2009 Nov; 33(11):1459-62. PubMed ID: 19446878
[TBL] [Abstract][Full Text] [Related]
37. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
38. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
40. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
